Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 30, 2012

ClinTec Sets Up Shop in Malawi

  • ClinTec International has expanded its operations into Malawi, increasing its presence in the markets of Africa, Asia, and the Middle East. The company is in the process of recruiting personnel with vaccine research experience to join its teams in Africa and Asia. Africa is a pivotal region for the development of adult and pediatric vaccines against infectious diseases.

    “I am pleased with our continued expansion in Africa and see huge potential for the company in conducting large scale vaccine trials,” said Rabinder Buttar, Ph.D. “Despite the challenging economic conditions through which many of our clients are restructuring their organizations, ClinTec continues to grow and win major new business from pharma companies. The company is continuing to expand into interesting new regions for clinical research. As the pharmaceutical industry increasingly focuses its drug development efforts on the emerging markets, ClinTec will closely partner with its clients, aligning its services and operations to fit with their needs.”

    ClinTec International is a CRO with a presence in over 40 developed and emerging countries, covering Western Europe, Central and Eastern Europe, the Middle East and Africa, Central and South Africa, Latin America, Asia, and the U.S.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »